The Imricor Medical Systems Inc (ASX: IMR) share price is in focus today after the company announced the commercial launch of its Interventional MR (iMR) lab solution in collaboration with global imaging leader Philips. This new combined solution is immediately available in CE-marked markets and is designed to support MR-guided cardiac interventions.

What did Imricor Medical Systems report?

• Commercial launch of a combined iMR lab solution with Philips.
• The solution integrates Philips’ 1.5T BlueSeal MR platform with Imricor’s NorthStar^®, Advantage-MR^®, and other systems.
• Includes Imricor’s single-use catheters and interventional tools for cardiac procedures.
• Available immediately in CE-marked markets; select configurations in the US now and more pending regulatory approval.
• Scalable platform for potential expansion into new procedures and clinical areas.

What else do investors need to know?

The launch builds on Imricor’s longstanding partnership with Philips, which began in 2012 with joint technology development. The iMR lab solution is designed specifically for cardiac electrophysiology and other interventional cardiac procedures, using MR-guided imaging for improved care.

This innovative, purpose-built approach aims to move MR imaging technology directly into the procedure room, making advanced interventions safer and more effective. The collaboration positions Imricor alongside a major industry player, broadening its reach and potential customer base.

What’s next for Imricor Medical Systems?

Imricor plans to showcase the new iMR lab solution at the ESC Congress 2026 in Munich. The company expects further configurations to be launched in the United States and other geographies as regulatory clearances are achieved.

Management sees this launch as a foundation for future growth, with ambitions to expand the platform into new clinical areas beyond cardiac electrophysiology. The partnership with Philips could pave the way for increased adoption of MR-guided interventions globally.

Imricor Medical Systems share price snapshot

Over the past 12 months, Imricor shares have risen 39%, outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab appeared first on The Motley Fool Australia.

More reading

• 2 ASX healthcare stocks tipped to return 34% to 63%
• Imricor Medical Systems shares: Philips declares compatibility for iMR products

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

If I were to retire with half a million dollars in superannuation savings, just how much passive income might I expect to earn each year?

It’s a question a lot of Aussies are asking themselves. Whether they’re close to retirement or still have many years to build up their super balance.

And, with history as our guide, the long-term answer is generally the same for folks looking to retire tomorrow or in 30 years.

Now, what we’re interested in here is the annual passive income that you can earn from your superannuation without drawing down on the existing $ 500,000 balance. That way, your income stream doesn’t shrink over time.

How do I create a reliable annual passive income stream?

While there are a few ways you might go about this, in my opinion buying the right basket of ASX dividend shares is the best path to achieving a reliable passive income stream in your golden years.

Atop their dividend payments, we’re also hoping to see some reasonable share price gains over time. Or at least enough to offset the impact of inflation on your superannuation investment and the resulting income stream.

While not written in stone, I’d tend to invest my superannuation savings in the larger end of the market, with stocks listed on the S&P/ASX 200 Index (ASX: XJO). These are normally less volatile than smaller dividend stocks. And you can screen for companies with reliable track records of making two (or more) dividend payouts each year.

I also prefer buying ASX dividend shares with franking credits. These give you credit for the taxes the companies you own have already paid on their profits.

Now, we’ll look at three quality ASX 200 dividend stocks that fit this bill below.

Just take note that the yields you often see are trailing yields. Future yields may be higher or lower depending on a range of company specific and macroeconomic factors.

And, of course, a properly diversified income portfolio will contain more than just three stocks.

With that said…

Investing that $500,000 of superannuation savings

The first quality ASX 200 dividend stock I’d consider buying is Bank of Queensland Ltd (ASX: BOQ).

Over the past 12 months, the ASX 200 bank stock has paid out a total of 55 cents a share in fully franked dividends (including a special dividend). At Thursday’s share price of $6.38, Bank of Queensland shares trade on a fully franked dividend yield of 8.6%.

The second stock I’d consider investing part of my $500,000 of superannuation into is Telstra Group Ltd (ASX: TLS).

Over the past 12 months the ASX 200 telco has paid (or shortly will pay) 21 cents a share in dividends, franked at 90%. At the recent Telstra share price of $4.58, the stock trades on a dividend yield of 4.6%.

And the third ASX 200 stock I’d target with my superannuation savings is Fortescue Ltd (ASX: FMG).

Over the past 12 months, the ASX 200 mining giant has paid (or soon will) a total of $1.08 a share in fully franked dividends. At the recent share price of $17.63, Fortescue shares trade on a fully franked dividend yield of 6.1%.

So, if you were to invest an equal amount of your superannuation savings into each of these three ASX 200 dividend stocks, you could expect to receive an average yield of around 6.4%.

Meaning your half million-dollar investment should see you earning $32,167 a year in passive income without drawing down that super balance.

The post How much passive income can I earn from $500,000 in superannuation? appeared first on The Motley Fool Australia.

More reading

• How much passive income can I earn off a $1 million superannuation balance?
• 37 ASX shares going ex-dividend next week
• How much is needed in superannuation for $2,500 in weekly passive income?
• How much superannuation is needed to target a $50,000 annual passive income?
• How much do I need to retire on $120,000 a year at 55?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It has been well documented the headwinds that have hit ASX healthcare shares in recent times. 

Rising interest rates, tighter capital markets, and a more challenging funding environment have weighed heavily on the sector. This has particularly impacted smaller, early-stage companies that remain reliant on external capital to fund growth. 

Yet, beneath the broader weakness, there are signs that the outlook is beginning to improve. Valuations have reset significantly, and a number of quality businesses now offer compelling long-term growth opportunities.

Two that fit this criteria are Mesoblast Ltd (ASX: MSB) and Sigma Healthcare Ltd (ASX: SIG). 

The team at Bell Potter have provided fresh guidance on both ASX healthcare stocks, tipping a big 12 months. 

Here’s what the broker had to say. 

Sigma Healthcare shares looking cheap 

Sigma Healthcare was formed in February 2025 following a merger of the legacy Sigma Healthcare with Chemist Warehouse Group. 

The merger integrates the distribution power of the legacy Sigma business with one of Australia’s most recognised retail pharmacy franchisors. 

In yesterday’s report, Bell Potter said the Chemist Warehouse merger is delivering scale, synergies, and operating leverage. Additionally, the pharmacy business is benefiting from structural growth. 

The broker saw full-year results as broadly in line with expectations, with revenue up 15.5% and normalised EPS rising 22% to 6.3 cents. 

Growth was driven by strong pharmacy sales. Net debt and leverage also improved materially, although most of the leverage reduction came from higher EBITDA rather than lower debt. Overall, Bell Potter sees a business with strong growth and improving efficiency that is now trading at its cheapest valuation since the merger.

Based on this guidance, Bell Potter has a buy recommendation on this ASX healthcare stock and a $3 price target. 

From current levels, this indicates 14% upside. 

Massive upside for Mesoblast 

This ASX healthcare stock has been relatively flat over the last year. 

It is a biotechnology company that develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

The company released annual results yesterday.

Bell Potter said the ASX healthcare company’s results were broadly in line with expectations.

The outlook remains very positive, with Ryoncil expected to deliver continued double-digit growth, and major catalysts ahead from Rexlemestrocel in heart failure and chronic lower back pain. 

The broker has issued a buy recommendation and set a $4.45 price target for this ASX healthcare stock. 

From yesterday’s closing price, this indicates over 84% upside. 

MSB has a long pipeline and label expansions for Ryoncil alone which we expect will come to market on a 3 to 5 year time horizon.

The post Why now is the time to buy low on these ASX healthcare shares with up to 84% upside appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• Where I’d invest $10,000 in ASX shares in September
• Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth
• Mesoblast earnings: Strong revenue growth and operational milestones in FY26
• ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.